Nanjing Synthgene Medical COVID -19 Antigen detection kit passed the laboratory test of Mahidol University in Thailand

Today, Nanjing Synthgene Medical’s SARS-COV-2 Nucleocapsid (N) Antigen Rapid Detection Kit (Colloidal gold method) Salivary was tested in the laboratory of Mahidol University in Thailand, and the test results showed 96.67% high sensitivity and 100% specificity, the quality of Nanjing Synthgene Medical products is highly recognized by the laboratory of Mahidol University in Thailand.

2021

Analysis on the situation of pharmaceutical foreign trade in the first quarter of 2011

In the first quarter of this year, the world economy continued to recover, the global pharmaceutical trade was heating up, the domestic pharmaceutical market developed rapidly, and the import demand for high-end pharmaceutical products increased sharply. my country's pharmaceutical trade achieved rapid growth in phases. The pharmaceutical foreign trade import and export volume reached 16.224 billion U.S. dollars, a year-on-year increase. An increase of 41.07%, of which exports were 10.119 billion U.S. dollars, an increase of 38.13% year-on-year, and imports were 6.105 billion U.S. dollars, an increase of 46.23% year-on-year. The growth rates of imports and exports were better than expected. At present, the competitive advantages of my country’s low- and mid-range pharmaceutical products are still relatively obvious, and they have been further strengthened in the process of the global pharmaceutical industry’s transfer to developing countries. In addition, my country’s pharmaceutical market has achieved remarkable results, and its exports to emerging pharmaceutical markets have developed rapidly, prompting my country’s original The export market for advantageous pharmaceutical products has further expanded. one. API products are ushering in a new growth stage, the market growth of developed countries is stable, and the emerging pharmaceutical market is developing rapidly The expansion of global generic drug market demand and industrial transfer provide opportunities and space for China's APIs to further expand into the international market. In the first quarter, my country's API exports were 5.363 billion US dollars, an increase of 31.31% year-on-year, realizing the export of APIs since the financial crisis The largest quarterly year-on-year increase. In terms of markets, exports to developed markets such as the European Union, the United States, and Japan rose steadily, with exports of US$1.414 billion, US$683 million, and US$311 million, respectively, with growth rates of 26.31%, 12.82%, and 3.23%, respectively, to the above three markets. The overall increase was 19.13%. Exports to major emerging pharmaceutical markets such as India, ASEAN, and Brazil were US$7.78, 5.03, and 158 million, up 39.15%, 45.64%, and 55.82% year-on-year, respectively. The total exports of the above three regions increased from 24.69% to 26.9%. The pharmaceutical market trade area is increasingly driving the export of raw materials and has become the regional market with the most development potential. At the same time, statistics show that the growth of the overall export volume of raw materials in the first quarter was mainly driven by export volume. The export volume increased by 39.53% and the export price fell by 5.89%. This further shows that the domestic fierce market competition has not changed, and the export phenomenon is prominent. In terms of main varieties, the export growth of traditional bulk commodities was weak. The export volume of 10 key products such as heparin sodium, vitamin C, vitamin E, and penicillin industrial salt increased by 7.23%, while the export price dropped by 16.51% and the export value dropped by 10.48%. There is a serious situation of homogeneous competition. On the other hand, the export of some APIs, such as macrolide antibiotics, hormones, chloramphenicol, and tetracycline APIs, has improved significantly, and the export prices have risen. The average prices have risen by 30.39%, 19.84%, and 31.24%, respectively. 40.05%, the export value increased by 100.35%, 23.69%, 60.72%, and 37.1% respectively. two. The export of high-end pharmaceutical products is differentiated, the export growth of preparations has declined, and the export situation of medical equipment is optimistic. In the first quarter, the export of high-end pharmaceutical products represented by western medicine preparations and diagnosis and treatment equipment diverged. Driven by the strong export of AstraZeneca Pharmaceutical Co., Ltd., the export of western medicine preparations increased by 23.71% in the first quarter. The export growth rate has declined compared with the same period last year. AstraZeneca Pharmaceutical Co., Ltd. among the foreign-funded enterprises took advantage of my country's strong raw material drug industry to transfer preparation production to China. In the first quarter, it added 73.5 million U.S. dollars in preparation exports, most of which were exported to Australia and quickly jumped to the export of western medicine preparations. First, it became the main driving force for the growth of preparations exports in the first quarter. If AstraZeneca's new export factors are not taken into account, the preparations exports in the first quarter only increased by 2%, which was a drop of nearly 1/3 compared with the same period last year. The export of preparations by state-owned and private enterprises still focuses on Asian, African and South American markets, and underdeveloped markets account

2020

Why the price of heparin sodium will reverse the rise

Since the 1990s, mad cow diseases in European and American countries have been one after another. In order to ensure the quality and safety of heparin sodium products, European and American pharmaceutical companies have completely stopped purchasing heparin sodium extracted from European and American beef intestines and beef lungs. This objectively promotes Chinese pigs. The price of small intestine heparin is stable and on the rise. At the end of March 2010, the global H1n1 influenza broke out in Mexico and the southwestern United States. The international market has erected a barrier to Mexico’s heparin exports. With the loss of Mexico’s heparin market share, a large number of heparin purchase orders have been concentrated in China. Suddenly, the demand for heparin has increased sharply, and major heparin export companies have also increased their purchase prices in order to obtain more heparin supplies.

2020

The United States Pharmacopeia publishes new heparin quality standards

In order to ensure the quality of heparin products and prevent potential contamination, the US Pharmacopoeia Commission decided to adopt new production control methods for heparin. The revised U.S. Pharmacopoeia standard has been announced and effective on October 1.

2020

China's bulk pharmaceutical raw materials varieties

Business News Agency, May 24: In 2011, there were 25 varieties of China's bulk pharmaceutical raw materials with an export value of more than 100 million U.S. dollars, an increase of three from 2010, mainly concentrated in vitamins, food additives and antibiotic raw materials. Heparin sodium once again topped the list with a total of 900 million US dollars, and citric acid rose from fourth to second last year; the two major vitamins-vitamin C and vitamin E moved to third and fourth place; vitamin B1 and Tai The export value of Lamectin exceeded 100 million U.S. dollars; the export value of penicillin industrial salt and azithromycin fell below 100 million U.S. dollars.

2020

< 1 2 >

Nanjing Synthgene Medical Technology Co., Ltd.

Nanjing Synthgene Medical Technology Co., Ltd. is a biomedical high-tech enterprise focusing on the development and production of OTC home self-inspection products. The company has a mature technology platform, including chromatography platform, isothermal amplification platform, etc.

Address：Building B6-2, No. 9, Weidi Road, Xianlin University Town, Xianlin Subdistrict, Qixia District, Nanjing City, China
Tel: +86(025)83696681 (overseas)
Email: info@syngenebio.com
After-sale Email ： service@syngenebio.com

Public Account

Business License

Messages

Tel

+86(025)83696681

E-mail

TOP